Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 9/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 8/20 | 0.71 |
| ▸ | PRKD2 | Q9BZL6 | 6/20 | 0.71 |
| ▸ | EGFR | P00533 | 5/20 | 0.71 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.58 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.58 |
| ▸ | MINK1 | Q8N4C8 | 6/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | MARK3 | P27448 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300350 | 0.83 | CSNK1D (1.00) | MAP4K4CSNK1DPRKD3PRKD2EGFR | |
| SCHEMBL4305791 | 0.80 | MAP4K4 (0.72) | MAP4K4CSNK1DPRKD3PRKD2EGFR | |
| SCHEMBL4296359 | 0.78 | MAP4K4 (1.00) | MAP4K4CSNK1DPRKD3PRKD2EGFR | |
| SCHEMBL4300430 | 0.74 | CSNK1D (0.85) | MAP4K4CSNK1DPRKD3PRKD2EGFR | |
| SCHEMBL4307588 | 0.74 | CSNK1D (0.84) | MAP4K4CSNK1DPRKD3PRKD2EGFR | |
| SCHEMBL3264591 | 0.74 | CSNK1D (1.00) | MAP4K4CSNK1DPRKD3PRKD2EGFR | |
| SCHEMBL4300553 | 0.71 | CSNK1D (0.78) | MAP4K4CSNK1DPRKD3PRKD2EGFR | |
| SCHEMBL9057179 | 0.71 | MAP4K4 (0.53) | MAP4K4CSNK1DPRKD3PRKD2EGFR | |
| SCHEMBL13958864 | 0.70 | MAP4K4 (0.49) | MAP4K4CSNK1DPRKD3PRKD2EGFR | |
| SCHEMBL4300339 | 0.69 | CSNK1D (0.77) | MAP4K4CSNK1DPRKD3PRKD2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | MAP4K4 24/4885CSNK1D 173/4885PRKD3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.